BioSpace News Archive

Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.

MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the treatment of chlorine-induced acute respiratory distress syndrome.

Codexis, Inc., a leading enzyme engineering company, announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, reported its financial results for the first quarter ended March 31, 2024, and provided a business update.

Aurinia Pharmaceuticals Inc., announced the presentation of results from an updated cost-effective analysis of LUPKYNIS, a second generation calcineurin inhibitor, at the annual National Kidney Foundation Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18.

FogPharma® and ARTBIO, Inc. announced a collaboration to co-develop Helicon-enabled ARTs to transform outcomes for patients with multiple types of cancer.

Caris Life Sciences® announced that the company and collaborators from the biopharma industry and leading cancer centers, including those within the Caris Precision Oncology Alliance™, will collectively present 41 studies across 19 tumor types at the 2024 American Society of Clinical Oncology Annual Meeting May 31 to June 4, 2024.

Rockwell Medical, Inc., a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced financial and operational results for the three months ended March 31, 2024.

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have resulted in full survival of lethally infected animals was achieved.

Passage Bio, Inc., a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, reported financial results for the first quarter ended March 31, 2024 and provided recent business highlights.